1. 標的：NASDAQ: TLSA (目前6.99)
Tiziana Life Sciences PLC
這不是特斯拉！
這不是特斯拉！
這不是特斯拉！
很重要說三遍～
2. 分類：拉回6.5以下多，目標12～15
3. 分析/正文：
—Seeking Alpha:
Tiziana Life SciencesNASDAQ:TLSA)oars 48%remarket on the heels ofubmitting a patent applicationor the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 alone or in combination with other anti-viral drugs.
The company has a worldwide exclusive license for nasal administration of Foralumab and other anti-CD3 mAbs for the treatment of neurodegenerative and other diseases.
Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of regulatory T-cells.
4. 進退場機制：-15%